MYEZOM BORTEZOMIB 3.5 MG INJECTION

Get a Price/Quote

MYEZOM BORTEZOMIB 3.5 MG INJECTION Specification

Indication
Multiple Myeloma, Mantle Cell Lymphoma

Origin
Pharmaceutical

Salt Composition
Bortezomib 3.5 mg

Dosage Form
Injection

Feature
Antineoplastic agent; administered intravenously or subcutaneously

Ingredients
Bortezomib

Application
Cancer treatment

Fermentation Smell
Odorless

Storage Instructions
Store below 25C, protect from light

Shelf Life
24 months

MYEZOM BORTEZOMIB 3.5 MG INJECTION Trade Information

Packaging Details
PACK OF 1 VIAL

Main Domestic Market
All India

About MYEZOM BORTEZOMIB 3.5 MG INJECTION

Myezom

This medication is a cancer chemotherapy drug used to treat certain types of tumors like multiple myeloma,mantle cell lymphoma. It blocks certain proteins which helps to slow the growth and spread of the cancer Available as: 2 Mg & 3.5 Mg

Specification

Product Name: Myezom
Contains: Bortezomib
Form: Vial
Strength:2 Mg & 3.5 Mg
Manufactured by :Dr.Reddys

NOTE:- Myezom is a prescription drug and should be used under proper medical guidance and advice. Do not share the medicine with others, since they may be suffering from a problem that is not effectively treated by this drug...............

Precise Cancer Therapy

MYEZOM BORTEZOMIB is an advanced cancer treatment tailored for patients diagnosed with multiple myeloma or mantle cell lymphoma. Its antineoplastic properties disrupt cancer cell growth and are administered under strict medical supervision in hospitals or oncology centers. Each vial is expertly prepared to ensure efficacy and safety, serving as a cornerstone in cancer management protocols.

Safe Handling and Administration

Proper reconstitution of MYEZOM is essential to guarantee optimal therapeutic action. Medical professionals must follow established protocols, using sterile 0.9% Sodium Chloride Injection to prepare the solution. The product can then be delivered intravenously or subcutaneously, adapting to individual patient requirements for maximum benefit and minimal discomfort.

Stringent Storage and Quality Standards

To maintain its effectiveness, MYEZOM should be stored at temperatures below 25C and protected from exposure to light. The injection has a 24-month shelf life, ensuring long-term usability under the correct conditions. Carefully formulated and regulated, this medication meets high pharmaceutical standards for quality and regulatory compliance.

FAQs of MYEZOM BORTEZOMIB 3.5 MG INJECTION:

Q: How should MYEZOM BORTEZOMIB 3.5 MG INJECTION be prepared for use?

A: MYEZOM must be reconstituted with sterile 0.9% Sodium Chloride Injection before administration. A qualified healthcare professional will perform this process under sterile conditions just prior to giving the dose.

Q: What are the main uses of MYEZOM BORTEZOMIB injection?

A: MYEZOM is primarily used in the treatment of multiple myeloma and mantle cell lymphoma, both forms of cancer requiring advanced oncological intervention.

Q: When should MYEZOM be administered and by whom?

A: Administration of MYEZOM is carried out in hospital or oncology centers and should always be performed by trained medical staff as per the prescribed schedule determined by an oncologist.

Q: Where should MYEZOM BORTEZOMIB be stored before use?

A: Store MYEZOM below 25C and protect the vial from light to maintain its stability and effectiveness. Follow specific hospital or pharmacy storage protocols.

Q: What is the route of administration for this injection?

A: MYEZOM can be administered intravenously (IV) or subcutaneously (SC), based on the healthcare providers recommendation and patient-specific factors.

Q: Why is a prescription required to obtain MYEZOM?

A: As an antineoplastic agent with significant effects and specific administration protocols, MYEZOM requires a doctors prescription to ensure safe and appropriate use tailored to the patients medical condition.

Q: What advantages does MYEZOM BORTEZOMIB offer in cancer treatment?

A: MYEZOM targets and inhibits cancer cell growth, offering a proven and effective option in the management of multiple myeloma and mantle cell lymphoma under regulated clinical supervision.

Tell us about your requirement